Oncobiologics

Q: What is Oncobiologics's official website?

Oncobiologics's official website is www.oncobiologics.com

Q: What is Oncobiologics's Revenue?

Oncobiologics's revenue is <$5 Million

Q: How many employees does Oncobiologics have?

Oncobiologics has 11-50 employees

Q: What industry does Oncobiologics belong to?

Oncobiologics is in the industry of: Manufacturing , Pharmaceuticals , Business Services

Q: What does Oncobiologics do?

Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. It is developing ONS-3010-adalimumab (Humira) biosimilar, a subcutaneous injectable mAb that binds to tumor necrosis factor-alpha, which has... completed Phase 1 clinical trial; and ONS-1045-bevacizumab (Avastin) biosimilar, a mAb administered by infusion that interferes with tumor growth by binding to vascular endothelial growth factor that has completed a Phase 1 clinical trial. The company also develops ONS-1050-trastuzumab (Herceptin) biosimilar, a mAb administered by infusion that binds to human epidermal growth factor receptor 2; and ONS-4010, a biosimilar to denosumab (Prolia/Xgeva), has cell lines developed with clone selection completed. It has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New... Read More

Q: Is Oncobiologics a public company?

Oncobiologics is private company therefore does not currently have an official ticker symbol

Manufacturing · 11-50 Employees

View Company Info for Free

Overview

Website

www.oncobiologics.com

Revenue

<$5 Million

Industry

Manufacturing

Pharmaceuticals

Business Services

Research & Development

ZI Rank: 1

Signal Type

Feb

Mar

Apr

May

Jun

Jul

ZI Rank

About Oncobiologics

Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. It is developing ONS-3010-adalimumab (Humira) biosimilar, a subcutaneous injectable mAb that binds to tumor necrosis factor-alpha, which has completed Phase 1 clinical trial; and ONS-1045-bevacizumab (Avastin) biosimilar, a mAb administered by infusion that interferes with tumor growth by binding to vascular endothelial growth factor that has completed a Phase 1 clinical trial. The company also develops ONS-1050-trastuzumab (Herceptin) biosimilar, a mAb administered by infusion that binds to human epidermal growth factor receptor 2; and ONS-4010, a biosimilar to denosumab (Prolia/Xgeva), has cell lines developed with clone selection completed. It has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang HRead more

Is this data correct?

View contact profiles from Oncobiologics

Popular SearchesOncobiologics IncSIC Code 28,283NAICS Code 32,325Show more

Oncobiologics Org Chart

Phone

Charles Mataya

Director, Financial Reporting

Phone

Get the full picture

Is Oncobiologics your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Click to see if Oncobiologics had a recent Job posting/layoffs

Check if Oncobiologics has recently received funding, and reach out quickly before it becomes old news!

Earning: See what the market has to say on Oncobiologics recently announced quarterly report

Funding: Get notified immidiatlly once Oncobiologics has new funding data

Check out if Oncobiologics is spiking on competitors!

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Website visits: Recent activity has been detected on your website

Product Launch: Get notified when Oncobiologics launches new products

Oncobiologics, which may be a good buyer, showed buying intent in Masked Content Topic

Congratulate Masked Content for being promoted to Masked Content at Oncobiologics

Recommended Actions

Introduce yourself to Masked Content, who has shown a strong intent to purchase lately

Find 3 more new buyers

View Email Formats for Oncobiologics

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Oncobiologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Oncobiologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncobiologics.